Harrow, Inc.

HROW ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-5.1M $-17.5M $-24.4M $-14.1M $-18.0M $-3.4M $168.0K $14.6M
Depreciation & Amortization $1.3M $1.3M $1.1M $1.3M $1.6M $1.7M $1.9M $1.6M
Depreciation — — — — — — — —
Amortization $17.0M $11.8M $10.1M $1.6M $161.0K $167.0K $209.0K $235.0K
Stock-Based Compensation $12.5M $17.6M $15.7M $8.0M $5.7M $2.8M $1.8M $2.5M
Net Cash from Operating Activities $43.9M $-22.2M $3.8M $1.7M $5.1M $-1.1M $950.0K $687.0K
Investing Activities
Capital Expenditures $887.0K $1.6M $1.5M $2.6M $1.8M $862.0K $1.5M $1.8M
Business Acquisitions $4.4M — — $6.0M — — — —
Net Cash from Investing Activities $-5.5M $-33.2M $-152.6M $-1.7M $-18.7M $-981.0K $-1.8M $-2.2M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-12.7M $28.5M $126.5M $54.1M $51.5M $1.4M $-1.0M $4.1M
Net Change in Cash $25.7M $-26.8M $-22.2M $54.1M $37.9M $-648.0K $-1.9M $2.6M
Free Cash Flow $43.0M $-23.8M $2.4M $-892.0K $3.3M $-2.0M $-518.0K $-1.1M
← Newer Page 1 of 2 Older →